Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 3/20 | 1.00 |
| ▸ | EGFR | P00533 | 13/20 | 0.71 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | PRNP | P04156 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | FLT1 | P17948 | 1/20 | 0.55 |
| ▸ | TEK | Q02763 | 1/20 | 0.55 |
| ▸ | GMNN | O75496 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9045125 | 0.83 | EGFR (1.00) | FADS1EGFRERBB2FBP1 | |
| Hydrochloric Acid SCHEMBL5467043 | 0.82 | EGFR (0.97) | FADS1EGFRERBB2FBP1 | |
| SCHEMBL30715841 | 0.82 | EGFR (0.69) | FADS1EGFRERBB2KDM4EHTT | |
| SCHEMBL27909532 | 0.80 | NTRK1 (0.69) | FADS1EGFRHTTCD38 | |
| SCHEMBL5315196 | 0.80 | EGFR (0.67) | FADS1EGFRNPC1HTTFLT1 | |
| SCHEMBL24466917 | 0.80 | EGFR (0.67) | FADS1EGFRKDM4EMAPTNPC1 | |
| SCHEMBL30715859 | 0.80 | NTRK1 (0.69) | FADS1EGFRHTTCD38 | |
| Hydrochloric Acid SCHEMBL5472994 | 0.79 | EGFR (0.65) | FADS1EGFRNPC1HTTFLT1 | |
| SCHEMBL18608697 | 0.78 | FADS1 (0.64) | FADS1EGFRFLT1TEKMKNK1 | |
| SCHEMBL29808690 | 0.78 | EGFR (0.64) | FADS1EGFRKDM4EMAPTFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | BUCK INST RES AGING (US) | 2024-07-04 | — | — | US | disclosed |
| WO-2009029617-A1 | DIARYLAMINE-SUBSTITUTED QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | LEXICON PHARMACEUTICALS, INC. | 2008-08-21 | — | — | US | disclosed |
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | LEXICON PHARMACEUTICALS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008089307-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF PAIN, INFLAMMATION AND CANCER | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008089310-A2 | DELTA 5 DESATURASE INHIBITORS FOR THE TREATMENT OF OBESITY | LEXICON PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194557-A1 | Methods and compositions for the treatment of pain, inflammation and cancer | TNF, IL6, CXCL8 | FADS1 1059/4885EGFR 1259/4885LCK 670/4885 |
| US-20240216316-A1 | DIHOMO-GAMMA LINOLENIC ACID (DGLA) IS A NOVEL SENOLYTIC | DAGLA, DAGLB, MGLL | FADS1 192/4885EGFR 2964/4885LCK 3307/4885 |
| US-20080200458-A1 | Methods and compositions for the treatment of body composition disorders | CPT1B, CPT1A, SHBG | FADS1 270/4885EGFR 3860/4885LCK 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.